MAP2K7 and neoplasm: This ability to overcome resistance was also seen in vivo with pan-RAF/MEK inhibitors, in part due to CD8+ TIL-mediated tumor regression with concomitant expansion of central memory T-cells and the regression of T-reg compartments.